HKSTP
23.9.2020 14:26:12 CEST | Business Wire | Press release
Hong Kong Science and Technology Parks Corporation (HKSTP) announced that the Elevator Pitch Competition 2020 (EPiC 2020) is now inviting applications from around the world. Given current global circumstances, HKSTP will stage the event on a virtual platform for the first time. Local and international startups and innovators can go beyond the geographic boundaries and unlock tremendous opportunities at EPiC 2020, which will take place from 6 to 13 November.
Marking its fifth anniversary, EPiC 2020 comprises a series of one-week events for the 150 contestants shortlisted from a competitive pool of global-wide applications. The startups will simulate the signature 60-second elevator ride to pitch their innovative business ideas virtually via a 1-minute video to a judging panel of major investors and industry leaders, who will select the top 10 finalists. The finalists will be announced during the final pitching competition on 6 November where they will battle to be named EPiC champion of 2020 in a 5-minute presentation plus a Q&A session.
Following the Pitching Competition, the contestants also have the chance to explore cross-border business and investment opportunities to help propel their technology innovation across all key stages of the entrepreneurial journey. The Global Matching Day programme, which will happen from 9 to 12 November, connects the best startups with thousands of leading investors and corporate leaders to explore business opportunities in the Greater Bay Area and Asia Pacific. The “Investment x Corporate Innovation Conference” on 13 November concludes the EPiC week by bringing together I&T heavyweights and global pioneers to discuss the regional investment opportunities and share the ways to drive corporate innovation and growth.
Albert Wong, CEO of HKSTP, said, “EPiC 2020, as our annual flagship event, is a unique platform to connect international innovation and technology (I&T) talent, startups and investors to accelerate global partnerships and collaborations. We are hosting our first-ever virtual EPiC this year to drive greater value and synergies among entrepreneurs and corporates across the globe in view of market challenges.”
“At HKSTP, our belief in entrepreneurial spirit and our commitment to sustaining the growth of the I&T ecosystem remain as strong as ever. We strive to provide a beacon of growth opportunity for startups around the world and support them across the critical early stages of their innovation journey.”
Last year, the competition attracted a record number of 650 entries from 48 countries and cities across the globe. Over 70% of the finalists were from 33 different overseas markets, including Australia, Canada, India, Japan, New Zealand, Singapore and the United States, among others. The event brought more than 1,000 entrepreneurs, venture capital firms, angel investors, industry players, incubators, accelerators and tech disruptors together, to sustain the I&T ecosystem in Hong Kong.
Who can apply:
- Tech startups that are less than five years old and have received less than US$10 million in funding by 31 March 2020 OR individuals who have not yet established any companies
- Ideas should focus on one of the four technology areas: Artificial Intelligence & Robotics, FinTech, Health Technology and Smart City.
Applications will close on 19 October 2020, at 23:59 hrs, Hong Kong time.
Please visit https://epic.hkstp.org/ for more detailed information on EPiC 2020.
List of awards and prizes
Award |
Cash Prize
|
Champion |
US$100,000 |
4 Tech Winners
|
US$10,000 |
Top 10 Finalists |
US$6,000 |
# # #
About Hong Kong Science and Technology Parks Corporation
Comprising Science Park, InnoCentre and Industrial Estates, Hong Kong Science & Technology Parks Corporation (HKSTP) is a statutory body dedicated to building a vibrant innovation and technology ecosystem to connect stakeholders, nurture technology talents, facilitate collaboration, and catalyse innovations to deliver social and economic benefits to Hong Kong and the region.
Established in May 2001, HKSTP has been driving the development of Hong Kong into a regional hub for innovation and growth in several focused clusters including Electronics, Information & Communications Technology, Green Technology, Biomedical Technology, Materials and Precision Engineering. We enable science and technology companies to nurture ideas, innovate and grow, supported by our R&D facilities, infrastructure, and market-led laboratories and technical centres with professional support services. We also offer value added services and comprehensive incubation programmes for technology start-ups to accelerate their growth.
Technology businesses benefit from our specialised services and infrastructure at Science Park for applied research and product development; enterprises can find creative design support at InnoCentre; while skill-intensive businesses are served by our three industrial estates at Tai Po, Tseung Kwan O and Yuen Long. More information about HKSTP is available at www.hkstp.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200923005526/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
